R-00179-2006 4 rate (decreased utilization of caloric substances in the body), with a consequent tendency for hypothermia. Central NPY administration induces food intake, tends to suppress metabolic rate (33) and enhances wakefulness (35) . Since basal metabolic rate (BMR) cannot be decreased by physiological means, injections of NPY can only suppress the excess metabolism above BMR, e.g. that seen during cold exposure or possibly during the active phase of the circadian cycle (33) . Understandably, the hypometabolic-hypothermic action can be demonstrated mainly in cool environments. Later on, the hyperhagia, hypometabolism and hypothermia are followed by a probably indirect catabolic effect causing a rise in metabolic rate and body temperature as well as a suppression of normal food intake for 12-24-h. At or near thermoneutrality only the catabolic effects are obvious (except for a persisting early hyperphagia), and here these appear somewhat earlier than in the cold.
Some, although not all (15) , data suggest that orexins possibly follow a similar anabolic pattern. Certain orexin actions are known to involve NPY mechanisms (39) . Central injections of orexin-A in rats enhanced food intake for about 30-60 min, and they induced hypometabolism and hypothermia for a similar period in rats kept slightly energy-deficient in a cool (but not at thermoneutral) environment (32) . However, similarly to NPY, they did not influence heat loss as represented by tail skin temperature. Central orexin injections also attenuated the experimental fever (13) . These primary orexin effects were followed by a secondary hypermetabolism and hyperthermia (32) , particularly at relatively warm ambient temperatures, possibly due to activation of catabolic neuropeptides like corticotrophinreleasing hormone (28) or to enhanced activity of prostaglandins (22) . In contrast, SB-334867, a food intake suppressing antagonist of orexin receptor (12), elevated thermogenesis (9). Although other data reported on hypermetabolism, hyperthermia (15, 22, 23) , or increased non-exercise activity thermogenesis (25) The other line of orexin effects appears to be more clear-cut: orexins have an outstanding role in sleep-wake regulation. The hypothalamic orexin levels of rats exhibited a circadian pattern: the levels gradually increased in the active phase and gradually decreased in the rest phase (7, 41). Orexin-deficient mice showed severe abnormalities of their sleep-wake cycle (5, 8) , with an enhanced number of behavioral phase shifts (20) . In patients with narcolepsycataplexy both the number of orexin neurons (36) and the orexin levels in the plasma (10) or cerebrospinal fluid (19) were decreased. In orexin neuron-ablated mice with narcolepsy and cataplexy exogenous orexin inhibited the cataplexy and improved wakefulness for hours (18) .
Conversely, SB-334867 prevented the orexin-induced reduction in paradoxical sleep and also the increase in latency of onset of such sleep (31) . Sleep deprivation causes a rise in hypothalamic orexin levels (37) , although the mediation of this process has not been clarified.
Since orexin-containing neurons have widespread connections between the hypothalamus and various sites of the central nervous system (2, 26) , it is likely that they have simultaneous effects in different systems. It still remains an open question whether or not the orexin effects related to energy balance and to sleep-wake cycle can be explained as concurrent but independent activities, or rather as interrelated ones. Since, however, the activity of orexin neurons is influenced fundamentally just by the main factors of energy balance, namely by monoamines, acetylcholine, nutrients, glucose, leptin, ghrelin (3, 29) , a rather strong coordination might be assumed to exist between the regulations of energy balance and sleep/wakefulness (38) . metabolic rate (approaching BMR) and/or by a rise in heat loss (21) . Orexins did not seem to influence heat loss mechanisms (32) . Since in the active phase the orexin levels increase gradually (7), participation of orexins in various phases might easily be understood, provided that orexins indeed enhance metabolic rate and body temperature. In this case, in the inactive phase the low orexin levels could contribute to a temperature fall -in orexin knockout mice a lack of fall in orexin level possibly explains the attenuated temperature fall during the resting period. Alternatively, orexins may be suppressors of metabolism. However, in the active phase the metabolic rate may depend on general activity (an enhancer of metabolic rate) and may be unrelated to presence of orexin, while the hypometabolic effects of the peptide may be more expressive in the inactive phase. In this phase sleep starts, but the gradually falling orexin levels, now unopposed by general activity, may still be high enough to contribute to a metabolic suppression. In orexin knockout mice the lack of such mechanism could also result in attenuation of temperature fall in the inactive period.
Apparently, the orexins (or their lack) seem to interfere normally mainly with processes of the inactive phase. Chronic orexin administration affected the daytime (inactive phase) food intake only, but it did not alter the whole-day consumption or the weight gain rate (40) . In accordance with the short time of effectiveness, chronic orexin administration failed to induce any time-consuming tonic alterations in thyroid activity or brown fat metabolism (27) . It follows that in the circadian temperature changes the orexins possibly play a more important role during rest than in the active period: their action may be limited to a temporary modification (suppression) of metabolic rate and body temperature, without altering heat loss.
Accordingly, a chronic lack of orexin effects should be presumed not to influence either the thyroid and brown fat functions or the metabolic rate during the active period. In contrast, they may be thought to impair the metabolic suppression during the rest period and to result in 
